Your browser doesn't support javascript.
loading
Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
Journal of Korean Medical Science ; : 1914-1921, 2016.
Artículo en Inglés | WPRIM | ID: wpr-24792
ABSTRACT
Extended-release osmotic extended-release oral delivery system (OROS) hydromorphone is a strong synthetic opioid designed to maintain a constant blood concentration by once daily dosing. The objective of this observational study was to investigate the clinical usefulness of OROS hydromorphone in patients with cancer pain of moderate to severe intensity. Patients with cancer pain who required strong opioids were administered with OROS hydromorphone for 4 weeks. We assessed changes in pain intensity using a numerical rating scale (NRS) as well as levels of sleep disturbance, breakthrough pain, end-of-dose failure, patient satisfaction, and overall assessment of drug effectiveness based on investigator evaluation. Of the 648 enrolled patients, 553 patients were included in the full analysis set. The mean pain intensity was significantly decreased from the NRS value of 5.07 ± 1.99 to 2.75 ± 1.94 (mean % change of 42.13 ± 46.53, P < 0.001). The degree of sleep disturbance significantly improved (mean NRS change of 1.61 ± 2.57, P < 0.001), and the incidence of breakthrough pain was significantly decreased (mean NRS change of 1.22 ± 2.30, P < 0.001). The experience of end-of-dose failure also significantly decreased from 4.60 ± 1.75 to 3.93 ± 1.70, P = 0.007). The patient satisfaction rate was 72.7%, and 72.9% of investigators evaluated the study drug as effective. OROS hydromorphone was an effective and tolerable agent for cancer pain management. It effectively lowered pain intensity as well as improved sleep disturbance, breakthrough pain, and end-of-dose failure (Identifier NCT 01273454).
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Investigadores / Incidencia / Satisfacción del Paciente / Hidromorfona / Dolor Irruptivo / Dolor Crónico / Manejo del Dolor / Estudio Observacional / Analgésicos Opioides Tipo de estudio: Ensayo Clínico Controlado / Estudio de incidencia / Estudio observacional / Estudio pronóstico Límite: Humanos Idioma: Inglés Revista: Journal of Korean Medical Science Año: 2016 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Investigadores / Incidencia / Satisfacción del Paciente / Hidromorfona / Dolor Irruptivo / Dolor Crónico / Manejo del Dolor / Estudio Observacional / Analgésicos Opioides Tipo de estudio: Ensayo Clínico Controlado / Estudio de incidencia / Estudio observacional / Estudio pronóstico Límite: Humanos Idioma: Inglés Revista: Journal of Korean Medical Science Año: 2016 Tipo del documento: Artículo